And Again

When it comes to retractions, former Duke University researcher Anil Potti is the gift that keeps on giving.

As fans of scientific malfeasance no doubt recall, Potti left Duke in 2010 amidst allegations that he had manipulated data in several lung cancer biomarker studies. Duke suspended Potti (who has since taken a job at the Cancer Center of North Dakota) along with clinical trials stemming from his research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.